Journal Home
Search for

Volume 77, Issue 2, Pages 119-128 (15 September 2005)


View previous. 2 of 28 View next.

Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia

Georges M. GharabawiaCorresponding Author Informationemail address, Cynthia A. Bossiea, Robert A. Lassera, Ibrahim Turkoza, Stephen Rodrigueza, Guy Chouinardb

Received 12 November 2004; received in revised form 8 March 2005; accepted 14 March 2005.

Abstract 

Assessing tardive dyskinesia (TD) has been complicated by the use of different research criteria and rating scales. We studied concordance between two commonly used scales, the Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS), to study interscale concordance and criteria to define TD.

Patients with schizophrenia or schizoaffective disorder (N=374) were rated at baseline with both scales. Linear and logistic regression models explored relationships between scale ratings and mapped scores for corresponding items. TD was defined as at least mild in ≥2 anatomical areas, or moderate or greater symptoms in ≥1 area at baseline. Logistic regression was used to find simplified criteria for predicting AIMS-defined TD by ESRS scores.

There was a strong association on corresponding item ratings. “Mild” was defined as AIMS score of 2 and ESRS 2 or 3, and “moderate or greater” as AIMS score ≥3 and ESRS ≥4. Using these criteria, there was 96.0% (359/374) agreement between AIMS- and ESRS-defined TD cases. The ESRS Clinical Global Impressions of severity of dyskinesia (CGI-SD) best predicted AIMS-defined TD. An ESRS CGI-SD ≥4 (95% CI: 3.61, 4.76) was associated with ≥95% probability of AIMS-defined TD.

High concordance between the scales for dyskinesia scores was found. Findings suggest that the ESRS CGI-SD score can serve as a simplified criterion for identifying AIMS-defined TD, and may be a useful tool for future research-based TD analyses, when occurring in the context of a full movement disorder assessment.

a Medical Affairs Division, Janssen Pharmaceutica Products, L.P., Titusville, NJ 08560, USA

b McGill University Health Center and University of Montreal, Centre de Recherche Fernand Séguin, Hôpital Louis-H Lafontaine, Montreal, QC, Canada

Corresponding Author InformationCorresponding author. 1125 Trenton-Harbourton Road, PO Box 200, Titusville, NJ 08560-0200, USA. Tel.: +1 609 730 3277; fax: +1 609 730 3125.

PII: S0920-9964(05)00118-0

doi:10.1016/j.schres.2005.03.008


View previous. 2 of 28 View next.